Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mesothelioma, Malignant”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Testing effectiveness (Phase 2)Ended earlyNCT01861301
What this trial is testing

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Who this might be right for
Epithelioid MesotheliomaRecurrent Malignant MesotheliomaSarcomatoid Mesothelioma+3 more
National Cancer Institute (NCI) 18
Not applicableStudy completedNCT01135849
What this trial is testing

B-Receptor Signaling in Cardiomyopathy

Who this might be right for
CarcinomasAmyloidosisAnal Cancer+35 more
Daniel Bernstein 99
Early research (Phase 1)Study completedNCT04242199
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMSI-H/dMMR TumorsCutaneous Squamous Cell Carcinoma+9 more
Incyte Corporation 182
Not applicableStudy completedNCT00897247
What this trial is testing

Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

Who this might be right for
Malignant MesotheliomaPulmonary Complications
Barbara Ann Karmanos Cancer Institute 494
Not applicableWithdrawnNCT01325753
What this trial is testing

Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body

Who this might be right for
Advanced Malignant MesotheliomaExtensive Stage Small Cell Lung CancerLung Metastases+4 more
Wake Forest University Health Sciences
Testing effectiveness (Phase 2)Ended earlyNCT03233724
What this trial is testing

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-Small Cell Lung Cancer+2 more
National Cancer Institute (NCI) 9
Early research (Phase 1)Ended earlyNCT04840615
What this trial is testing

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Who this might be right for
Mesothelioma
National Cancer Institute (NCI) 2
Early research (Phase 1)UnknownNCT02395679
What this trial is testing

Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients

Who this might be right for
Mesothelioma
Erasmus Medical Center 9
Early research (Phase 1)Study completedNCT00020124
What this trial is testing

Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs

Who this might be right for
Lung CancerMalignant MesotheliomaMetastatic Cancer
National Institutes of Health Clinical Center (CC)
Not applicableStudy completedNCT00372840
What this trial is testing

Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

Who this might be right for
Breast CancerColorectal CancerLung Cancer+4 more
Fox Chase Cancer Center 340
Large-scale testing (Phase 3)Study completedNCT02709512
What this trial is testing

Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Who this might be right for
Mesothelioma
Polaris Group 249
Not applicableStudy completedNCT00477919
What this trial is testing

E-MOSAIC Electronic Tool to Monitor Symptoms

Who this might be right for
Cancer
Swiss Cancer Institute 264
Early research (Phase 1)UnknownNCT03852823
What this trial is testing

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Who this might be right for
Advanced Solid TumoursCervical CancerMalignant Mesothelioma+2 more
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 192
Testing effectiveness (Phase 2)Study completedNCT02347917
What this trial is testing

BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Who this might be right for
Malignant Pleural MesotheliomaNon-Small Cell Lung Cancer
Sumitomo Pharma Co., Ltd. 28
Early research (Phase 1)Study completedNCT01521325
What this trial is testing

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Who this might be right for
MesotheliomaPancreatic CancerOvarian Cancer+1 more
Morphotek 6
Testing effectiveness (Phase 2)Study completedNCT01139775
What this trial is testing

A Study in Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 76
Not applicableLooking for participantsNCT07330271
What this trial is testing

PTC-Guided Therapy for Peritoneal Mesothelioma

Who this might be right for
Peritoneal Mesothelioma
Beijing Tsinghua Chang Gung Hospital 347
Testing effectiveness (Phase 2)Study completedNCT04115111
What this trial is testing

Diadem to Investigate the Activity and Safety of Durvalumab

Who this might be right for
Pleura Mesothelioma
Mario Negri Institute for Pharmacological Research 57
Testing effectiveness (Phase 2)Looking for participantsNCT04515836
What this trial is testing

Olaparib in Patients With HRD Malignant Mesothelioma

Who this might be right for
MesotheliomaHomologous Recombination Deficiency
University of Chicago 56
Next Page